You can tell a lot about a surfactant from its profile. Volume requirements, dosing schedule, and concentration of key ingredients may affect your experience with a surfactant.

Take a closer look at the profile of CUROSURF and consider how your experience with CUROSURF may be different than with other exogenous surfactants.

CUROSURF has the lowest volume per dose1

CUROSURF® (poractant alfa) Intratracheal Suspension1 Survanta® (beractant) Intratracheal Suspension2 Infasurf® (calfactant) Intratracheal Suspension3
1st dose* (mL/kg) 2.5 4 3
2nd dose* (mL/kg) 1.25 4 3
Schedule Q12 hours Q6 hours Q12 hours
Single bolus delivery option Yes No No
  • Clinical studies have not established that lower volume or fewer doses result in superior efficacy or safety based on clinically relevant end points

Examine other differences between exogenous surfactants1-5

CUROSURF® (poractant alfa) Intratracheal Suspension1,4 Survanta® (beractant) Intratracheal Suspension2,4 Infasurf® (calfactant) Intratracheal Suspension3,4
Source Porcine Bovine Bovine
Phospholipid concentration (mg/mL) 76 25 35
Dipalmitoylphos-phatidylcholine (mg/mL) 30 11.0-15.5 16
SP-B (mg/mL) 0.45 Not Specified 0.26
SP-C (μg protein/μmol. L-1 phospholipid) 5.0-11.6 1.0-20.0 8.1
Additives No Yes No
Organic solvent extraction Yes Yes Yes
Liquid-gel chromatography Yes No No
  • An initial dose of CUROSURF delivers more than twice the phospholipid concentration (mg/mL) of other exogenous surfactants, and 44% more surfactant protein B (SP-B) than Infasurf1-3
  • While clinical studies have demonstrated that SP-B, SP-C, and phospholipids are essential elements, they have not established the quantity required for optimal surfactant efficacy
  • CUROSURF is the only exogenous surfactant to undergo a liquid-gel chromatography purification step during manufacturing1-5
  • Liquid-gel chromatography allows CUROSURF to maintain a much higher concentration of polar lipids vs other exogenous surfactants1,3,5,6

*Based on 1000-gram infant and manufacturer’s dosing schedule. Volume of surfactant is measured in milliliters per kilogram of body weight at birth.

Neutral lipids such as triacylglycerol, cholesterol, and cholesteryl esters are filtered out of CUROSURF via liquid-gel chromatography. CUROSURF contains a higher proportion of polar lipids as a result of chromatography. In contrast, Survanta and Infasurf retain their neutral lipids and have relatively lower polar lipids.3,5,6


CUROSURF® (poractant alfa) is intended for intratracheal use only. The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung compliance. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to respond to respiratory changes.

CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm infants.

Transient adverse reactions associated with administration of CUROSURF include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring.

Pulmonary hemorrhage, a known complication of premature birth and very low birth-weight, has been reported with CUROSURF. The rates of common complications of prematurity observed in a multicenter single-dose study that enrolled infants 700–2000 g birth weight with RDS requiring mechanical ventilation and FiO2 ≥ 0.60 are as follows for CUROSURF 2.5 mL/kg (200 mg/kg) (n=78) and control (n=66; no surfactant) respectively: acquired pneumonia (17% vs. 21%), acquired septicemia (14% vs. 18%), bronchopulmonary dysplasia (18% vs. 22%), intracranial hemorrhage (51% vs. 64%), patent ductus arteriosus (60% vs. 48%), pneumothorax (21% vs. 36%) and pulmonary interstitial emphysema (21% vs. 38%).


CUROSURF® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.

Please see Full Prescribing Information.

References: 1. CUROSURF® (poractant alfa) Intratracheal Suspension Prescribing Information, Chiesi USA, Inc. May 2021. 2. Survanta® (beractant) Intratracheal Suspension Prescribing Information, AbbVie, Inc. October 2020. 3. Infasurf ® (calfactant) Intratracheal Suspension Prescribing Information, ONY, Inc, March 2018. 4. Taeusch HW, Lu K, Ramierez-Schrempp D. Acta Pharmacol Sin. 2002;23(suppl):11-15. 5. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K; And The North American Study Group. Am J Perinatol. 2004;21:109-119. 6. Wiseman LR, Bryson HM. Drugs. 1994;48:386-403. 7. IQVIA Global Market Share, Total Year 2018.